Clinical trial of trimetazidine tablets in the treatment of coronary heart disease with heart failure and atrial fibrillation
10.13699/j.cnki.1001-6821.2018.03.008
- VernacularTitle:曲美他嗪片治疗冠心病伴心力衰竭合并心房颤动的临床研究
- Author:
Li-Zhi LIU
1
;
Dan ZHANG
;
Ju-Fei WANG
;
Cheng JIANG
;
Cao-Jie LU
;
Jia-Cai CHEN
;
Wu-Bin WU
;
Hai-Hui MAO
;
Jing-Xing CUI
Author Information
1. 奉化市人民医院心内科
- Keywords:
trimetazidine tablet;
coronary heart disease;
heart failure;
atrial fibrillation;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(3):218-220
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of trimetazidine tablets in the treatment of coronary heart disease with heart failure and atrial fibrillation.Methods A total of 226 patients of coronary heart disease with heart failure and atrial fibrillation were randomly divided into control and treatment groups with 113 cases per group.Control group was treated with aspirin,clopidogrel,statins,angiotensin converting enzyme inhibitor and other conventional therapy.Treatment group was given trimetazidine 20 mg per time,tid,orally,on the basis of control group.Two groups were treated for 6 months.The clinical efficacy,6 min walk test,metabolic syndrome (Mets) score,lipoprotein associated phospholipase A2 (Lp-PLA2),NT-brain natriuretic peptide (NT-proBNP),tumor necrosis factor-α (TNF-α) and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of treatment and control groups were 84.07％ (95 cases/ll3 cases) and 65.49％ (74 cases/ll3 cases) with significant difference (P ＜ 0.05).After treatment,the main indexes in treatment and control groups were compared:the distance of 6 min walking test were (378.45 ± 82.31) and (352.14 ± 63.23) m,Mets score were (2.14 ± 0.50) and (1.82 ± 0.28) points,Lp-PLA2 were (397.24 ± 135.98) and (481.20 ± 139.15) U · L-1,NT-proBNP were (2084.35 ±1074.47) and (4611.25 ±1299.74) pg· mL-1,TNF-α were (12.94 ±6.03) and (23.10±6.78) ng · mL-1,the differences were statistically significant (all P ＜ 0.05).There were no adverse drug reactions in two groups during the treatment.Conclusion Trimetazidine tablets have a definitive clinical efficacy and safety in the treatment of coronary heart disease with heart failure and atrial fibrillation.
